Additional file 3: Table S2. of Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods

Discordance between pulmonary flow-based mitral regurgitation volume (MRvol) grades in all HCM patients. (DOCX 15 kb

Additional file 2: Table S1. of Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods

Discordance between aortic flow-based mitral regurgitation volume (MRvol) grades in all HCM patients. (DOCX 16 kb

Additional file 1: Figure S1. of Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods

Representative curves of aortic (left) and pulmonary (right) flow in non-obstructive (upper row, blue lines) and obstructive (lower row, red lines) HCM patients. In a patient with obstructive HCM, early peak flow is seen, with a subsequent decrease caused by the outflow tract obstruction. (PDF 18 kb

Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations

<div><p><i>TTN</i> gene truncating variants are common in dilated cardiomyopathy (DCM), although data on their clinical significance is still limited. We sought to examine the frequency of truncating variants in <i>TTN</i> in patients with DCM, including familial DCM (FDCM), and to look for genotype-phenotype correlations. Clinical cardiovascular data, family histories and blood samples were collected from 72 DCM probands, mean age of 34 years, 45.8% FDCM. DNA samples were examined by next generation sequencing (NGS) with a focus on the <i>TTN</i> gene. Truncating mutations were followed up by segregation study among family members. We identified 16 <i>TTN</i> truncating variants (<i>TTN</i> trunc) in 17 probands (23.6% of all cases, 30.3% of FDCM, 17.9% of sporadic DCM). During mean 63 months from diagnosis, there was no difference in adverse cardiac events between probands with and without TTN truncating mutations. Among relatives 29 mutation carriers were identified, nine were definitely affected (31%), eight probably affected (27.6%) one possibly affected (3.4%) and eleven were not affected (37.9%). When relatives with all affected statuses were combined, disease penetrance was still incomplete (62.1%) even after exclusion of unaffected relatives under 40 (82%) and was higher in males versus females. In all mutation carriers, during follow-up, 17.4% had major adverse cardiac events, and prognosis was significantly worse in men than in women. In conclusion, <i>TTN</i> truncating variants were observed in nearly one fourth of young DCM patient population, in vast majority without conduction system disease. Incomplete penetrance suggests possible influence of other genetic and/or environmental factors on the course of cardiotitinopathy. Counseling should take into account sex and incomplete penetrance.</p></div

Comparison of clinical data on <i>TTN</i> trunc positive versus <i>TTN</i> trunc negative DCM probands.

<p>Comparison of clinical data on <i>TTN</i> trunc positive versus <i>TTN</i> trunc negative DCM probands.</p

List of <i>TTN</i> truncating variants identified in the study group annotated to transcript NM_001267550.2.

<p>List of <i>TTN</i> truncating variants identified in the study group annotated to transcript NM_001267550.2.</p

Clinical characteristics of affected and not affected <i>TTN</i> trunc positive relatives.

<p>Clinical characteristics of affected and not affected <i>TTN</i> trunc positive relatives.</p

Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN</i> truncating variants, males and females, p = 0.018, log-rank test = -2.37.

<p>Kaplan-Meier cumulative survival curves for SAE (HF death, OHT or LVAD) in 46 carriers of <i>TTN</i> truncating variants, males and females, p = 0.018, log-rank test = -2.37.</p